The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The cannabinoid receptor type 1 (CB1) and its endogenous ligands, the endocannabinoids, are involved in the regulation of food intake. Here we show that the lack of CB1 in mice with a disrupted CB1 gene causes hypophagia and leanness. As compared with WT (CB1+/+) littermates, mice lacking CB1 (CB1-/-) exhibited reduced spontaneous caloric intake and, as a consequence of reduced total fat mass, decreased body weight. In young CB1-/- mice, the lean phenotype is predominantly caused by decreased caloric intake, whereas in adult CB1-/- mice, metabolic factors appear to contribute to the lean phenotype. No significant differences between genotypes were detected regarding locomotor activity, body temperature, or energy expenditure. Hypothalamic CB1 mRNA was found to be coexpressed with neuropeptides known to modulate food intake, such as corticotropin-releasing hormone (CRH), cocaine-amphetamine-regulated transcript (CART), melanin-concentrating hormone (MCH), and preproorexin, indicating a possible role for endocannabinoid receptors within central networks governing appetite. CB1-/- mice showed significantly increased CRH mRNA levels in the paraventricular nucleus and reduced CART mRNA levels in the dorsomedial and lateral hypothalamic areas. CB1 was also detected in epidydimal mouse adipocytes, and CB1-specific activation enhanced lipogenesis in primary adipocyte cultures. Our results indicate that the cannabinoid system is an essential endogenous regulator of energy homeostasis via central orexigenic as well as peripheral lipogenic mechanisms and might therefore represent a promising target to treat diseases characterized by impaired energy balance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878 · cited 1×
“CART mRNA was abundantly expressed in the hypothalamus, especially in the supraoptic nucleus, PVN, VMN, dorsomedial nucleus (DMN), LHA, and ARC (30), whereas the expression of prepro-orexin and MCH mRNAs was restricted to the neurons localized in LHA and in the zona incerta (31, 32).”
BackgroundLedent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 2×
“Male mice deficient for CB1 (CB1–/–) and male WT littermates (CB1+/+), originally generated and genotyped as described earlier (19), were used.”
MethodSelf-citationLeptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559 · cited 3×
“Importantly, the levels of hypothalamic endocannabinoids were shown to be decreased after leptin administration, and the blockade of CB1 was demonstrated to inhibit starvation-induced hyperphagia in mice (17).”
BackgroundInfluentialBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 1×
“These observations, together with the presence of monoacylglycerol lipase in fat tissue, one of the main endocannabinoid-degrading enzymes (38, 39), strongly support adipose tissue as a novel physiologic and pharmacologic target for cannabinoid action.”
Background
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…affect lipid metabolism through regulating the level of adiponectin production (Bensaid et al., 2003), by increasing lipoprotein lipase activity (Cota et al., 2003), or by inhibiting AMPactivated protein kinase (AMPK) (Kola et al., 2005), which leads to increased lipogenesis and decrease in…”
BackgroundInfluentialThe orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
“Recently, the liver and adipose has been added to the list (Cota et al., 2003; Osei-Hyiaman et al., 2005).”
BackgroundEndocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
The Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
Flier, J. S. (2004) · Cell · doi:10.1016/s0092-8674(03)01081-x · Cited by 1,112
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
“, or to minimize the impact of the stressful stimulus by reinforcing appetite through inhibition of anorectic signal”
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Self-citationDrug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Endocannabinoid control of food intake and energy balance
Di Marzo, V., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 743
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
The endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691
“…CB1 receptor activation is known to increase lipogenesis-induced lipid accumulation in both liver (OseiHyiaman et al, 2005, 2008) and fat cells (Cota et al, 2003; Bouaboula et al, 2005; Gary-Bobo et al, 2006; Matias et al, 2006; Bellocchio et al, 2008; Pagano et al, 2008), we investigated…”
BackgroundActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686
Matias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
Self-citationCannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrié, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802583 · Cited by 583
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Silvestri, C., & Di Marzo, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.001 · Cited by 543
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Blüher, M., Engeli, S., Klöting, N., Berndt, J., Fasshauer, M., Bátkai, S., Pacher, P., Schön, M. R., Jordan, J., & Stumvoll, M. (2006) · Diabetes · doi:10.2337/db06-0812 · Cited by 530
Bays, H. E., González-Campoy, J. M., Bray, G. A., Kitabchi, A. E., Bergman, D. A., Schorr, A. B., Rodbard, H. W., & Henry, R. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.343 · Cited by 530
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Kola, B., Hubina, E., Tucci, S. A., Kirkham, T. C., Garcia, E. A., Mitchell, S. E., Williams, L. M., Hawley, S. A., Hardie, D. G., Grossman, A. B., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500175200 · Cited by 472
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., Marsicano, G., Lutz, B., Buettner, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34827 · Cited by 458
Self-citationSVIZENSKA, I., DUBOVY, P., & SULCOVA, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 457
Tam, J., Vemuri, V. K., Liu, J., Bátkai, S., Mukhopadhyay, B., Godlewski, G., Osei-Hyiaman, D., Ohnuma, S., Ambudkar, S. V., Pickel, J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42551 · Cited by 454
Regulation of adipocyte lipolysis
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J.-A., Fernández, S., & Rodríguez, A. (2014) · Nutrition Research Reviews · doi:10.1017/s095442241400002x · Cited by 429
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Jourdan, T., Godlewski, G., Cinar, R., Bertola, A., Szanda, G., Liu, J., Tam, J., Han, T., Mukhopadhyay, B., Skarulis, M. C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3265 · Cited by 388
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Liking vs. wanting food: Importance for human appetite control and weight regulation
Finlayson, G., King, N., & Blundell, J. E. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.03.004 · Cited by 374
Hormonal regulation of food intake
Stanley, S., Wynne, K., McGowan, B., & Bloom, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2004 · Cited by 372
Endocannabinoids–at the crossroads between the gut microbiota and host metabolism
Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367
Endocannabinoids and the control of energy balance
Matias, I., & Di Marzo, V. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.11.006 · Cited by 365
Review article: The impact of obesity on reproduction in women with polycystic ovary syndrome
Pasquali, R., Gambineri, A., & Pagotto, U. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00990.x · Cited by 359
Self-citationPeripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance
Tam, J., Cinar, R., Liu, J., Godlewski, G., Wesley, D., Jourdan, T., Szanda, G., Mukhopadhyay, B., Chedester, L., Liow, J.-S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.002 · Cited by 356
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Jbilo, O., Ravinet‐Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Le Fur, G., Galiègue, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3177fje · Cited by 346
Leptin controls adipose tissue lipogenesis via central, STAT3–independent mechanisms
Buettner, C., Muse, E. D., Cheng, A., Chen, L., Scherer, T., Pocai, A., Su, K., Cheng, B., Li, X., Harvey-White, J., et al. (2008) · Nature Medicine · doi:10.1038/nm1775 · Cited by 342
Hill, M. N., & Tasker, J. G. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.030 · Cited by 341
Xue, B., & Kahn, B. B. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.113217 · Cited by 338
“administration of ghrelin increases food intake and body weight (Cummings et al. 2001; Nakazato et al. 2001; Cummings et al. 2002; Cota et al. 2003).”
BackgroundCannabinoids, opioids and eating behavior: The molecular face of hedonism?
Cota, D., Tschöp, M. H., Horvath, T. L., & Levine, A. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.10.004 · Cited by 330
Self-citationThe Human Obesity Gene Map: The 2004 Update
Pérusse, L., Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Snyder, E. E., & Bouchard, C. (2005) · Obesity Research · doi:10.1038/oby.2005.50 · Cited by 330
Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary Report
Hill, M., Miller, G., Ho, W.-S., Gorzalka, B., & Hillard, C. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-993211 · Cited by 292
Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence
Le Foll, B., & Goldberg, S. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077974 · Cited by 291
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 287
Taschler, U., Radner, F. P. W., Heier, C., Schreiber, R., Schweiger, M., Schoiswohl, G., Preiss-Landl, K., Jaeger, D., Reiter, B., Koefeler, H. C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215434 · Cited by 282
The endocannabinoid system in obesity and type 2 diabetes
Di Marzo, V. (2008) · Diabetologia · doi:10.1007/s00125-008-1048-2 · Cited by 281
Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin
Burdyga, G., Lal, S., Varro, A., Dimaline, R., Thompson, D. G., & Dockray, G. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5404-03.2004 · Cited by 280
Geurts, L., Neyrinck, A. M., Delzenne, N. M., Knauf, C., & Cani, P. D. (2014) · Beneficial Microbes · doi:10.3920/bm2012.0065 · Cited by 277
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
Sipe, J. C., Waalen, J., Gerber, A., & Beutler, E. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802954 · Cited by 259
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
Juan-Picó, P., Fuentes, E., Javier Bermúdez-Silva, F., Javier Díaz-Molina, F., Ripoll, C., Rodríguez de Fonseca, F., & Nadal, A. (2006) · Cell Calcium · doi:10.1016/j.ceca.2005.10.005 · Cited by 258
Non-Alcoholic Fatty Liver Disease
Engin, A. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-48382-5_19 · Cited by 248
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246
“…of the hypothalamic-pituitary-adrenal (HPA) axis; in particular, endocannabinoid/CB1 receptor signaling inhibits activation of the HPA axis while loss of CB1 receptors and CB1 receptor antagonists enhance HPA axis reactivity (Patel et al. 2004, 2005b; Cota et al. 2003, 2007; Steiner et al. 2008a).”
BackgroundBrown fat biology and thermogenesis
Richard, D. (2011) · Frontiers in Bioscience · doi:10.2741/3786 · Cited by 247
“The CB1 receptor mRNA is expressed in various brain regions and neuron types (195, 239-241).”
BackgroundHill, M. N., & McEwen, B. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.001 · Cited by 235
“, 1998); however, the CB1 receptor is also known to exhibit some expression patterns in peripheral tissue, such as immune cells, vascular tissue and adipocytes (Cota et al., 2003; Hillard, 2000; Parolaro, 1999).”
BackgroundIntegration of Endocannabinoid and Leptin Signaling in an Appetite-Related Neural Circuit
Jo, Y.-H., Chen, Y.-J. J., Chua, S. C., Talmage, D. A., & Role, L. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.021 · Cited by 234
Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230
Cannabinoid activation of PPARα; a novel neuroprotective mechanism
Sun, Y., Alexander, S. P. H., Garle, M. J., Gibson, C. L., Hewitt, K., Murphy, S. P., Kendall, D. A., & Bennett, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707478 · Cited by 229
“The endogenous cannabinoid system is also involved in the control of energy balance as demonstrated by reductions in calorie intake, total fat mass and body weight in CB1-null mice (Cota et al., 2003b).”
BackgroundLipid signaling in adipose tissue: Connecting inflammation & metabolism
Masoodi, M., Kuda, O., Rossmeisl, M., Flachs, P., & Kopecky, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.09.023 · Cited by 221
“2) and degradation (FA amide hydrolase) of endocannabinoids and its main receptor CB1 was demonstrated in adipocytes and WAT [130,149–151].”
BackgroundCB1 cannabinoid receptor‐mediated modulation of food intake in mice
Wiley, J. L., Burston, J. J., Leggett, D. C., Alekseeva, O. O., Razdan, R. K., Mahadevan, A., & Martin, B. R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706157 · Cited by 221
Pagano, C., Pilon, C., Calcagno, A., Urbanet, R., Rossato, M., Milan, G., Bianchi, K., Rizzuto, R., Bernante, P., Federspil, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0768 · Cited by 210
“Enzymatic pathways for the synthesis of endogenous cannabinoids and CNR1 are expressed in peripheral tissues involved in energy metabolism (liver, adipose tissue, and skeletal muscle) (4, 7).”
BackgroundInfluentialAn overview of the cannabinoid type 2 receptor system and its therapeutic potential
Bie, B., Wu, J., Foss, J. F., & Naguib, M. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000616 · Cited by 206
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205
Self-citationEndocannabinoids selectively enhance sweet taste
Yoshida, R., Ohkuri, T., Jyotaki, M., Yasuo, T., Horio, N., Yasumatsu, K., Sanematsu, K., Shigemura, N., Yamamoto, T., Margolskee, R. F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912048107 · Cited by 200
“E such as anandamide [N-arachidonoylethanolamine (AEA)] and 2-arachidonoyl glycerol (2-AG) are known orexigenic mediators that act via CB1 receptors in hypothalamus and limbic forebrain to induce appetite (1, 2) and stimulate food intake (3).”
BackgroundVan Gaal, L., Pi-Sunyer, X., Després, J.-P., McCarthy, C., & Scheen, A. (2008) · Diabetes Care · doi:10.2337/dc08-s258 · Cited by 199
“adipocytes (8), liver (9), pancreas (10), brain (11), gut (12), and skeletal muscle (13).”
BackgroundEndocannabinoids in liver disease
Tam, J., Liu, J., Mukhopadhyay, B., Cinar, R., Godlewski, G., & Kunos, G. (2011) · Hepatology · doi:10.1002/hep.24077 · Cited by 194
“The major pathway is CB1 activation of LPL in adipose tissue, which results in increased FA release and transfer to the liver.(71) Additional mechanisms mediated via hepatic CB1 receptors include increased de novo hepatic lipogenesis, decreased FA oxidation,(2) and decreased secretion of TG-rich VLDL.”
Cannabinoids and appetite: food craving and food pleasure
Kirkham, T. C. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782810 · Cited by 189
“Endocannabinoid-opioid interactions in eating motivation Unsurprisingly, feeding effects of endocannabinoids have been linked functionally to other neurotransmitters that contribute to the control of food intake (Tucci et al., 2004; Cota et al., 2003; Di Marzo & Matias, 2005).”
BackgroundEndocannabinoid system, stress and HPA axis
Micale, V., & Drago, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.039 · Cited by 189
Shearman, L. P., Rosko, K. M., Fleischer, R., Wang, J., Xu, S., Tong, X. S., & Rocha, B. A. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200312000-00001 · Cited by 186
“, 2003), as well as decreases in fat mass and body weight (Cota et al., 2003).”
BackgroundThe expression of receptors for endocannabinoids in human and rodent skeletal muscle
Cavuoto, P., McAinch, A. J., Hatzinikolas, G., Janovská, A., Game, P., & Wittert, G. A. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.099 · Cited by 177
Plant, Synthetic, and Endogenous Cannabinoids in Medicine
Marzo, V. D., & Petrocellis, L. D. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.011205.135648 · Cited by 169
Hypothalamic inflammation: a double‐edged sword to nutritional diseases
Cai, D., & Liu, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06388.x · Cited by 159
Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn076 · Cited by 156
Tedesco, L., Valerio, A., Cervino, C., Cardile, A., Pagano, C., Vettor, R., Pasquali, R., Carruba, M. O., Marsicano, G., Lutz, B., et al. (2008) · Diabetes · doi:10.2337/db07-1623 · Cited by 145
Self-citationArmario, A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.04.005 · Cited by 131
Nicotine and cannabinoids: parallels, contrasts and interactions
VIVEROS, M., MARCO, E., & FILE, S. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.08.002 · Cited by 106
Thornton-Jones, Z. D., Kennett, G. A., Benwell, K. R., Revell, D. F., Misra, A., Sellwood, D. M., Vickers, S. P., & Clifton, P. G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.06.001 · Cited by 83
Murdolo, G., Kempf, K., Hammarstedt, A., Herder, C., Smith, U., & Jansson, P. A. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347440 · Cited by 58
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807120200 · Cited by 53
Atkinson, T. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00412.x · Cited by 49
“Rimonabant is also shown to inhibit enzymes involved in lipogenesis, demonstrating the peripheral metabolic antagonistic effects (91).”
The Treatment of Obesity and Its Co-Occurrence With Substance Use Disorders
VanBuskirk, K. A., & Potenza, M. N. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181ce38e7 · Cited by 48
Role of lipid-derived mediators in skeletal muscle insulin resistance
Taube, A., Eckardt, K., & Eckel, J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2009 · Cited by 40
Verty, A. N. A., Boon, W. M., Mallet, P. E., McGregor, I. S., & Oldfield, B. J. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06750.x · Cited by 39
Pucci, M., Micioni Di Bonaventura, M. V., Vezzoli, V., Zaplatic, E., Massimini, M., Mai, S., Sartorio, A., Scacchi, M., Persani, L., Maccarrone, M., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00523 · Cited by 38
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Metadata
- Authors
- Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., Tomassoni, F., Cervino, C., Nisoli, E., Linthorst, A. C. E., Pasquali, R., Lutz, B., Stalla, G. K., & Pagotto, U.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-08-01
- Volume
- 112
- Issue
- 3
- Pages
- 423-431
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2073734463
- Cited by
- 1,168
- References
- 49
- FWCI
- 40.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.